Completed PHASE1 INTERVENTIONAL 2-arm NCT01430195

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV) (CUV102)

Proof of Concept Study to Compare Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Nonsegmental Vitiligo

Sponsor: Clinuvel Pharmaceuticals Limited

Conditions Vitiligo

Interventions Afamelanotide Narrow-Band UVB Light Treatment

Updated 6 times since 2017 Last updated: Mar 21, 2013 Started: Jun 30, 2011 Primary completion: May 31, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01430195, this PHASE1 trial focuses on Vitiligo and remains completed. Sponsored by Clinuvel Pharmaceuticals Limited, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinuvel Pharmaceuticals Limited

Data source: Clinuvel Pharmaceuticals Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Detroit, United States
• New York, United States